Skip to main
HQY

HealthEquity (HQY) Stock Forecast & Price Target

HealthEquity (HQY) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 33%
Buy 53%
Hold 7%
Sell 0%
Strong Sell 7%

Bulls say

HealthEquity Inc. demonstrated strong financial performance with a 13% year-over-year increase in custodial revenue, contributing to an impressive adjusted EBITDA margin of 44.0%, reflecting a 466 basis point improvement compared to the previous year. In the most recent quarterly report, total revenue rose 7.2% year-over-year to $322.2 million, surpassing both estimates and consensus expectations, driven largely by custodial revenue growth. The company's total accounts also increased by 5.0% year-over-year to 17.280 million, highlighting the expansion in its consumer-directed benefit accounts and underscoring the positive momentum in customer engagement and revenue generation.

Bears say

HealthEquity's stock outlook remains negative due to its shares trading at 6.4x FY/26 revenue estimates and 15.1x adjusted EBITDA estimates, which are significantly lower than its high-growth SaaS peer group averages of 7.6x and 29.7x, respectively. Additionally, the company's financial performance has been impacted by a one-time legal settlement costing $30 million, indicating potential vulnerabilities in operational stability. Despite slight upward revisions in revenue and adjusted EBITDA estimates, the overall growth projections and current valuation metrics suggest a lack of competitive positioning relative to its peers, raising concerns for future performance.

HealthEquity (HQY) has been analyzed by 15 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 53% recommend Buy, 7% suggest Holding, 0% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of HealthEquity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HealthEquity (HQY) Forecast

Analysts have given HealthEquity (HQY) a Buy based on their latest research and market trends.

According to 15 analysts, HealthEquity (HQY) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $118.93, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $118.93, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HealthEquity (HQY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.